Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Sorafenib Her2-receptor negative breast cancer not applicable detail...
ERBB2 neg Ramucirumab + Docetaxel Her2-receptor negative breast cancer no benefit detail...
Unknown unknown Bevacizumab + Docetaxel + Fluorouracil + Epirubicin + Cyclophosphamide Her2-receptor negative breast cancer sensitive detail...
ERBB2 neg Exemestane + Seribantumab Her2-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown Cisplatin + Veliparib + Vinorelbine Her2-receptor negative breast cancer not applicable detail...
BRCA1 mutant Cisplatin + Veliparib + Vinorelbine Her2-receptor negative breast cancer sensitive detail...
BRCA2 mutant Cisplatin + Veliparib + Vinorelbine Her2-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown Vantictumab + Paclitaxel Her2-receptor negative breast cancer not applicable detail...
ERBB2 neg ERBB2 pos LY411575 + Paclitaxel Her2-receptor negative breast cancer sensitive detail...
ERBB2 neg ERBB2 pos RO4929097 + Paclitaxel Her2-receptor negative breast cancer sensitive detail...
AKT1 E17K Ipatasertib Her2-receptor negative breast cancer sensitive detail...
ERBB2 neg Sorafenib + Vinorelbine Her2-receptor negative breast cancer predicted - sensitive detail...
BRCA1 mutant Olaparib Her2-receptor negative breast cancer sensitive detail...
BRCA2 mutant Olaparib Her2-receptor negative breast cancer sensitive detail...
Unknown unknown Capivasertib + Paclitaxel Her2-receptor negative breast cancer not applicable detail...
Unknown unknown Paclitaxel + Reparixin Her2-receptor negative breast cancer not applicable detail...
FGFR1 amp Pazopanib Her2-receptor negative breast cancer sensitive detail...
ERBB2 mutant Neratinib Her2-receptor negative breast cancer sensitive detail...
ERBB2 D769H Neratinib Her2-receptor negative breast cancer no benefit detail...
ERBB2 G778_P780dup Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 L755_E757delinsS Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 L755S Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 L841V Neratinib Her2-receptor negative breast cancer no benefit detail...
ERBB2 L869R Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 S310F Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 V777L Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 Y772_A775dup Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
ERBB2 exon 20 ins Neratinib Her2-receptor negative breast cancer predicted - sensitive detail...
RB1 K240Sfs*22 TP53 R248W Fulvestrant + Palbociclib Her2-receptor negative breast cancer predicted - resistant detail...
RB1 E268* RB1 I101fs RB1 T738_R775del RB1 V654fs Fulvestrant + Palbociclib Her2-receptor negative breast cancer predicted - resistant detail...
RB1 H483Y Letrozole + Ribociclib Her2-receptor negative breast cancer predicted - resistant detail...
BRCA1 inact mut Talazoparib Her2-receptor negative breast cancer sensitive detail...
BRCA2 inact mut Talazoparib Her2-receptor negative breast cancer sensitive detail...
FBXW7 mutant LY3039478 Her2-receptor negative breast cancer predicted - sensitive detail...
AKT1 E17K Capivasertib Her2-receptor negative breast cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00764972 Phase Ib/II Sorafenib + Vinorelbine Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer Unknown status
NCT00921115 Phase II Anastrozole Fulvestrant Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Active, not recruiting
NCT00971737 Phase II Trastuzumab Cyclophosphamide Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer Unknown status
NCT01036087 Phase II Panitumumab + Abraxane + Carboplatin Fluorouracil + Epirubicin + Cyclophosphamide Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer Active, not recruiting
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting
NCT01145430 Phase I pegylated liposomal doxorubicin + Veliparib Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Completed
NCT01262027 Phase II Dovitinib TKI258 for Metastatic Inflammatory Breast Cancer Patients Active, not recruiting
NCT01272037 Phase III Anastrozole Letrozole Tamoxifen Exemestane Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01351909 Phase Ib/II Cyclophosphamide Veliparib Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting
NCT01437566 Phase II GDC-0980 Fulvestrant Pictilisib Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy Completed
NCT01441947 Phase II cabozantinib + Fulvestrant Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Active, not recruiting
NCT01467310 Phase I Trametinib Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 Completed
NCT01479244 Phase III E75 Sargramostim Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Completed
NCT01484041 Phase Ib/II Dovitinib Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer Terminated
NCT01528345 Phase II Fulvestrant + Dovitinib Fulvestrant Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Terminated
NCT01560416 Phase II Fulvestrant Ganetespib Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Completed
NCT01572727 Phase II Buparlisib + Paclitaxel Paclitaxel A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Completed
NCT01610284 Phase III Fulvestrant + BKM120 Fulvestrant Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Active, not recruiting
NCT01633060 Phase III Fulvestrant Fulvestrant + BKM120 A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Terminated
NCT01670877 Phase II Neratinib Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Recruiting
NCT01674140 Phase III Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting
NCT01698918 Phase II Exemestane + Everolimus Everolimus + Letrozole Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Active, not recruiting
NCT01757327 Phase II Sonidegib LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Withdrawn
NCT01776008 Phase II Goserelin + MK2206 Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Terminated
NCT01779050 Phase II Trastuzumab Docetaxel Epirubicin + Cyclophosphamide Paclitaxel Fluorouracil + Epirubicin + Cyclophosphamide Docetaxel + Carboplatin Docetaxel + Cyclophosphamide Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Active, not recruiting
NCT01791478 Phase I Letrozole + BYL719 BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting
NCT01792050 Phase II Docetaxel indoximod Paclitaxel Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Unknown status
NCT01797120 Phase II Fulvestrant + Everolimus Fulvestrant Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Completed
NCT01803282 Phase I GS-5745 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed FOLFIRI Nab-paclitaxel + Gemcitabine Paclitaxel + Carboplatin Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Active, not recruiting
NCT01823835 Phase II GDC-0810 A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Active, not recruiting
NCT01837602 Phase I cMet CAR RNA T Cells Targeting Breast Cancer Completed
NCT01894451 Phase I Bevacizumab Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy Active, not recruiting
NCT01905592 Phase III Niraparib A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Active, not recruiting
NCT01918306 Phase Ib/II Cisplatin Cisplatin + Pictilisib GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Terminated
NCT01923168 Phase II BKM120 + Letrozole Letrozole Letrozole + BYL719 Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Completed
NCT01928394 Phase Ib/II Ipilimumab Nivolumab A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01953588 Phase III Anastrozole Fulvestrant Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting
NCT01958021 Phase III Ribociclib Letrozole Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Active, not recruiting
NCT01963481 Phase II Cyclophosphamide Exemestane Exemestane and Cyclophosphamide for Metastatic Breast Cancer Completed
NCT01964924 Phase II Trametinib + GSK2141795 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting
NCT01969643 Phase I SGN-LIV1A A Safety Study of SGN-LIV1A in Breast Cancer Patients Recruiting
NCT02010021 Phase I Letrozole Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. Completed
NCT02032277 Phase III Doxorubicin + Cyclophosphamide Veliparib Carboplatin Paclitaxel + Carboplatin A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer Active, not recruiting
NCT02032823 Phase III Olaparib Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn
NCT02049957 Phase Ib/II MLN0128 + Fulvestrant MLN0128 + Exemestane Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer Completed
NCT02057133 Phase I Abemaciclib + Letrozole Abemaciclib + Exemestane Everolimus + Exemestane + LY2835219 Abemaciclib + Anastrozole Abemaciclib + Tamoxifen Abemaciclib + Trastuzumab A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread Recruiting
NCT02074878 Phase I Sunitinib + Crizotinib CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer Terminated
NCT02088684 Phase Ib/II BKM120 + Fulvestrant + LEE011 Fulvestrant + Ribociclib BYL719 + Fulvestrant + LEE011 Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Completed
NCT02095184 Phase I Anastrozole Letrozole GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients Recruiting
NCT02107703 Phase III Abemaciclib Fulvestrant A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Active, not recruiting
NCT02115048 Phase II Afatinib Letrozole Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone Completed
NCT02120417 Phase II Ruxolitinib + Capecitabine Capecitabine A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Terminated
NCT02137837 Phase III Fulvestrant + Everolimus Fulvestrant + Everolimus + Anastrozole Fulvestrant S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended
NCT02142868 Phase III Palbociclib + Letrozole Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate No longer available
NCT02154776 Phase I LEE011 + BKM120 + Letrozole Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet) Completed
NCT02157051 Phase I Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer Recruiting
NCT02163694 Phase III Veliparib Paclitaxel + Carboplatin A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Active, not recruiting
NCT02178722 Phase Ib/II Pembrolizumab Epacadostat A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) Active, not recruiting
NCT02187991 Phase II Alisertib Paclitaxel Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Active, not recruiting
NCT02188745 Phase II Exemestane Estradiol Anastrozole Letrozole ER Reactivation Therapy for Breast Cancer Recruiting
NCT02204098 Phase I Letrozole Anastrozole Goserelin Exemestane Tamoxifen Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Recruiting
NCT02236572 Phase II Everolimus Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score Unknown status
NCT02246621 Phase III Abemaciclib + Anastrozole + Letrozole Anastrozole + Letrozole A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer Active, not recruiting
NCT02248090 Phase I AZD9496 AZD9496 First Time in Patients Ascending Dose Study Active, not recruiting
NCT02258451 Phase II Exemestane + Everolimus radium Ra 223 dichloride Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer Active, not recruiting
NCT02258464 Phase II radium Ra 223 dichloride Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer Active, not recruiting
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02260661 Phase I Fulvestrant AZD8835 Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours Completed
NCT02269670 Phase II Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy Active, not recruiting
NCT02273752 Phase II Everolimus Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated
NCT02273973 Phase II Taselisib Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) Completed
NCT02276443 Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy Recruiting
NCT02278120 Phase III Tamoxifen Letrozole Ribociclib Goserelin Anastrozole Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Active, not recruiting
NCT02282345 Phase II Talazoparib Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation Active, not recruiting
NCT02286843 Phase I Trastuzumab Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? Recruiting
NCT02291913 Phase II Everolimus + Tamoxifen Anastrozole + Everolimus Fulvestrant + Everolimus Everolimus + Letrozole Everolimus + Toremifene Exemestane + Everolimus Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Active, not recruiting
NCT02296801 Phase II Palbociclib Letrozole A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer Active, not recruiting
NCT02301988 Phase II Paclitaxel Ipatasertib A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer Completed
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Active, not recruiting
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed
NCT02311933 Phase II Z-endoxifen HCl Tamoxifen Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer Active, not recruiting
NCT02323191 Phase I Atezolizumab LY3022855 A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors Active, not recruiting
NCT02352025 Phase I S-equol S-equol in Women With Triple Negative Breast Cancer Recruiting
NCT02374099 Phase II Azacitidine Fulvestrant Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant Terminated
NCT02379247 Phase Ib/II BYL719 + nab-paclitaxel BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer Active, not recruiting
NCT02384239 Phase II Fulvestrant Palbociclib Tamoxifen A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Recruiting
NCT02384746 Phase I Fulvestrant + Ixazomib Phase I Study of the Combination of MLN9708 and Fulvestrant Recruiting
NCT02389764 Phase II Nintedanib Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC) Terminated
NCT02401347 Phase II Talazoparib Talazoparib Beyond BRCA (TBB) Trial Recruiting
NCT02402764 Phase II Selinexor Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC Active, not recruiting
NCT02403271 Phase Ib/II Ibrutinib + MEDI4736 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed
NCT02422615 Phase III Ribociclib Fulvestrant Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer. Active, not recruiting
NCT02437318 Phase III Alpelisib Fulvestrant Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Active, not recruiting
NCT02441946 Phase II Abemaciclib Loperamide Anastrozole A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Completed
NCT02448771 Phase Ib/II Bazedoxifene + Palbociclib A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer Active, not recruiting
NCT02453620 Phase I Entinostat Nivolumab + Ipilimumab Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Recruiting
NCT02457910 Phase Ib/II Enzalutamide Taselisib Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Active, not recruiting
NCT02463032 Phase II enobosarm Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer Active, not recruiting
NCT02476786 Phase II Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Recruiting
NCT02481050 Phase II Eribulin Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer Completed
NCT02513394 Phase III Palbociclib PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS) Recruiting
NCT02520063 Phase Ib/II Letrozole Carotuximab Everolimus Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer Recruiting
NCT02536794 Phase II Durvalumab + Tremelimumab MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer Recruiting
NCT02561832 Phase I Cyclophosphamide Olaparib Carboplatin A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer Completed
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02599714 Phase Ib/II Fulvestrant + Palbociclib Vistusertib Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR) Active, not recruiting
NCT02619669 Phase I Sapanisertib Letrozole Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer Recruiting
NCT02626507 Phase I Palbociclib Gedatolisib Goserelin Fulvestrant Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer Recruiting
NCT02630693 Phase II Palbociclib Fulvestrant Tamoxifen Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer Active, not recruiting
NCT02632045 Phase II Fulvestrant Ribociclib Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer Recruiting
NCT02648477 Phase II Bevacizumab Letrozole Anastrozole Exemestane Doxorubicin Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Recruiting
NCT02651610 Phase II Bavituximab Paclitaxel Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Withdrawn
NCT02668666 Phase II Palbociclib + Tamoxifen Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Recruiting
NCT02684032 Phase I Letrozole Fulvestrant Gedatolisib + Palbociclib A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer Recruiting
NCT02692755 Phase II Palbociclib + Letrozole Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA) Active, not recruiting
NCT02712723 Phase II Letrozole + Ribociclib Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer Recruiting
NCT02732119 Phase Ib/II LEE011 + Everolimus + Exemestane Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1) Active, not recruiting
NCT02738866 Phase II Fulvestrant + Palbociclib Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor Recruiting
NCT02747004 Phase II Abemaciclib + Loperamide Abemaciclib Abemaciclib + Tamoxifen A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1) Active, not recruiting
NCT02752685 Phase II nab-paclitaxel + Pembrolizumab Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Recruiting
NCT02753686 Phase I Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Exemestane + Everolimus Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) Recruiting
NCT02756364 Phase II MLN0128 + Fulvestrant Fulvestrant MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy Active, not recruiting
NCT02760030 Phase II Fulvestrant + Palbociclib Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery Recruiting
NCT02764541 Phase II Palbociclib Letrozole Tamoxifen Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) Recruiting
NCT02776917 Phase I Cirmtuzumab + Paclitaxel Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Recruiting
NCT02778685 Phase II Letrozole + Palbociclib + Pembrolizumab Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib Recruiting
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Recruiting
NCT02792114 Phase I Rimiducid Mesothelin CAR-T cells Cyclophosphamide T-Cell Therapy for Advanced Breast Cancer Recruiting
NCT02792725 Expanded access Abemaciclib Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer Approved for marketing
NCT02811497 Phase II Azacitidine + MEDI4736 Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Recruiting
NCT02824575 Phase I Paclitaxel + Rebastinib Eribulin + Rebastinib Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Recruiting
NCT02860000 Phase II Alisertib + Fulvestrant Alisertib Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Recruiting
NCT02871791 Phase Ib/II Exemestane + Everolimus + Palbociclib Palbociclib With Everolimus + Exemestane In BC Recruiting
NCT02892734 Phase II Nivolumab + Ipilimumab Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Recruiting
NCT02936206 Phase I Tamoxifen Fulvestrant Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Recruiting
NCT02941926 Phase III Ribociclib + Letrozole + Goserelin Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Active, not recruiting
NCT02942355 Phase II Anastrozole + Palbociclib Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Recruiting
NCT02953860 Phase II Enzalutamide + Fulvestrant Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer Recruiting
NCT02955394 Phase II Fulvestrant Enzalutamide + Fulvestrant Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer Recruiting
NCT02957968 Phase II Paclitaxel + Doxorubicin + Cyclophosphamide Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting
NCT02983604 Phase Ib/II Exemestane GS-5829 + Fulvestrant GS-5829 + Exemestane Fulvestrant GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer Terminated
NCT03007979 Phase II Goserelin Fulvestrant + Palbociclib Palbociclib + Letrozole Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Recruiting
NCT03018080 Phase II Paclitaxel + Pembrolizumab Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy) Recruiting
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03051659 Phase II Eribulin Eribulin + Pembrolizumab A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Recruiting
NCT03051672 Phase II Pembrolizumab Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Recruiting
NCT03056755 Phase II Alpelisib + Fulvestrant Letrozole + BYL719 Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant Recruiting
NCT03070002 Phase II Denosumab Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells Terminated
NCT03078751 Phase III Ribociclib Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1) Active, not recruiting
NCT03092934 Phase Ib/II AK-01 A Study of AK-01 in Solid Tumors Active, not recruiting
NCT03128619 Phase Ib/II Copanlisib + Palbociclib + Letrozole Copanlisib + Letrozole Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Recruiting
NCT03132467 Phase I Durvalumab + Tremelimumab Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer Recruiting
NCT03147287 Phase II Palbociclib Fulvestrant + Palbociclib Fulvestrant + Palbociclib + Avelumab Fulvestrant Palbociclib After CDK and Endocrine Therapy (PACE) Recruiting
NCT03166085 Phase I PU-H71 + nab-paclitaxel PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer Recruiting
NCT03225547 Phase II Mifepristone + Pembrolizumab Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer Recruiting
NCT03241810 Phase II Fulvestrant Fulvestrant + Seribantumab Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) Recruiting
NCT03280563 Phase Ib/II Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab + Exemestane Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab + Fulvestrant Atezolizumab + Bevacizumab + Tamoxifen Atezolizumab + Ipatasertib + Fulvestrant Fulvestrant Atezolizumab + Fulvestrant A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Recruiting
NCT03285412 Ribociclib CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer Recruiting
NCT03285607 Phase I Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110 MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Withdrawn
NCT03286842 Phase III Olaparib To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. Recruiting
NCT03294694 Phase I Fulvestrant + PDR001 + Ribociclib PDR001 + Ribociclib Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Recruiting
NCT03329937 Phase I Niraparib Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment Recruiting
NCT03332797 Phase I GDC-9545 + Palbociclib GDC-9545 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer Recruiting
NCT03337724 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) Recruiting
NCT03344536 Debio 1347 + Fulvestrant A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer Recruiting
NCT03393845 Phase II Fulvestrant + Pembrolizumab Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients Recruiting
NCT03430518 Phase I Durvalumab + Eribulin Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Recruiting
NCT03455270 Phase I G1T48 G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer Recruiting
NCT03471663 Phase I D-0502 + Palbociclib D-0502 A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer Recruiting
NCT03473639 Phase I Capecitabine + Entinostat A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast 49) Recruiting
NCT03519178 Phase II PF-06873600 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy Recruiting
NCT03524170 Phase I M7824 RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Recruiting
NCT03554044 Phase I Letrozole + talimogene laherparepvec talimogene laherparepvec + Tamoxifen Exemestane + talimogene laherparepvec Fulvestrant + talimogene laherparepvec Anastrozole + talimogene laherparepvec Paclitaxel + talimogene laherparepvec Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer Not yet recruiting
NCT03560531 Phase I Palbociclib + ZN-c5 ZN-c5 A Study of ZN-c5 in Subjects With Breast Cancer Recruiting
NCT03566485 Phase Ib/II Atezolizumab + Idasanutlin Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Recruiting
NCT03628066 Phase II Goserelin Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer Recruiting
NCT03633331 Phase II Fulvestrant + Letrozole + Palbociclib Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Recruiting
NCT03650894 Phase II Bicalutamide + Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Not yet recruiting
NCT03659136 Phase II Everolimus + Exemestane + Xentuzumab Exemestane + Everolimus The XENERA-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Recruiting
NCT03685331 Phase I Fulvestrant + Olaparib + Palbociclib Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Not yet recruiting
NCT03685591 Phase I Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 Palbociclib PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Recruiting
NCT03701334 Phase III Ribociclib A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) Recruiting
NCT03774472 Phase Ib/II Hydroxychloroquine + Letrozole + Palbociclib Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer Recruiting
NCT03789110 Phase II Nivolumab + Ipilimumab NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Not yet recruiting